&NA;ER 30346 (BMS 207147) is an orally active triazole antifungal agent with broad spectrum activity that is undergoing phase I investigation with Eisai in Japan and with Bristol-Myers Squibb in the USA. Bristol-Myers Squibb have licensed ER 30346 from Eisai for development worldwide, except for Japan where ER 30346 will continue to be developed by Eisai. ER 30346 has potential in the treatment of systemic fungal infections such as candidiasis, aspergillosis and cryptococcal meningitis and in the treatment of oropharyngeal candidiasis.